Published online before print March 13, 2006, doi: 10.1161/CIRCULATIONAHA.105.583732
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:1442-1450.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Important Role of Endogenous Erythropoietin System in Recruitment of Endothelial Progenitor Cells in Hypoxia-Induced Pulmonary Hypertension in Mice
From the Departments of Cardiovascular Medicine (K. Satoh, Y.K., M.N., Y.I., J.O., H.T., A.K., J.W., K. Shirato, H.S.), Pathology (M.O.), and Microbiology and Immunology (N.I., K. Sugamura), Tohoku University Biomedical Engineering Research Organization (TUBERO) (N.M.), Tohoku University Graduate School of Medicine, Sendai, Japan, and the Center for Tsukuba Advanced Research Alliance (N.S., M.Y.), University of Tsukuba, Tsukuba, Japan.
Correspondence to Hiroaki Shimokawa, MD, PhD, Professor and Chairman, Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. E-mail shimo{at}cardio.med.tohoku.ac.jp
Received August 18, 2005; revision received December 17, 2005; accepted January 20, 2006.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Recent studies have suggested that endogenous erythropoietin (Epo) plays an important role in the mobilization of bone marrow–derived endothelial progenitor cells (EPCs). However, it remains to be elucidated whether the Epo system exerts protective effects on pulmonary hypertension (PH), a fatal disorder encountered in cardiovascular medicine.
Methods and Results— A mouse model of hypoxia-induced PH was used for study. We evaluated right ventricular systolic pressure, right ventricular hypertrophy, and pulmonary vascular remodeling in mice lacking the Epo receptor (EpoR) in nonerythroid lineages (EpoR–/– rescued mice) after 3 weeks of exposure to hypoxia. Those mice lack EpoR in the cardiovascular system but not in the hematopoietic system. The development of PH and pulmonary vascular remodeling were accelerated in EpoR–/– rescued mice compared with wild-type mice. The mobilization of EPCs and their recruitment to the pulmonary endothelium were significantly impaired in EpoR–/– rescued mice. By contrast, reconstitution of the bone marrow with wild-type bone marrow cells ameliorated PH in the EpoR–/– rescued mice. Hypoxia enhanced the expression of EpoR on pulmonary endothelial cells in wild-type but not EpoR–/– rescued mice. Finally, hypoxia activated endothelial nitric oxide synthase in the lungs in wild-type mice but not in EpoR–/– rescued mice.
Conclusions— These results indicate that the endogenous Epo/EpoR system plays an important role in the recruitment of EPCs and prevents the development of PH during chronic hypoxia in mice in vivo, suggesting the therapeutic importance of the system for the treatment of PH.
Key Words: hypertension, pulmonary • hypoxia • endothelium • vasculature • remodeling
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Erythropoietin (Epo) has long been regarded as a hypoxia-induced hormone that acts exclusively in the proliferation and differentiation of erythroid progenitors.1 However, recent studies have demonstrated the expression of the Epo receptor (EpoR) in the cardiovascular system,2,3 and the therapeutic potential of Epo has been noted in a variety of disorders, including cerebral infarction, myocardial ischemia/reperfusion, and congestive heart failure.4–6 We also have recently demonstrated the protective role of endogenous Epo in patients with acute myocardial infarction.7 However, the potential protective role of the endogenous Epo/EpoR system against pulmonary hypertension (PH) remains to be examined.
Clinical Perspective p 1450
Hypoxia has been considered to increase plasma levels of Epo and hematocrit, resulting in enhanced blood viscosity and PH.8 However, exogenous Epo does not accelerate hypoxia-induced PH in rats.9 Rather, Epo exerts direct protective effects on endothelial cells10,11 and enhances the mobilization of endothelial progenitor cells (EPCs)12 and their proliferative and adhesive capacity,13 thus promoting endothelial repair and postnatal vasculogenesis.14,15 Pulmonary endothelium is important in the maintenance of pulmonary vasculature,16 whereas endothelial dysfunction accelerates pulmonary vascular remodeling in hypoxia-induced PH.17 Therefore, it is conceivable that Epo has protective effects on pulmonary endothelial cells and inhibits the development of PH.
Hypoxia induces vascular endothelial growth factor (VEGF) and Epo,18 thus promoting mobilization of EPCs and their homing to the ischemic tissue.12,19 Recent studies have shown that intravenously injected EPCs home to pulmonary vasculature and ameliorate pulmonary vascular remodeling in monocrotaline-induced PH, demonstrating a potential role of exogenous EPCs as a source of pulmonary endothelial cells in vivo.20,21 In the present study, we thus examined our hypothesis that the endogenous Epo/EpoR system plays an important protective role against the development of hypoxia-induced PH. For this purpose, we used EpoR-null mutant mice expressing EpoR exclusively in the erythroid lineage (EpoR–/– rescued mice).22
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Preparation
All procedures were performed according to the protocols approved by the Institutional Committee for Use and Care of Laboratory Animals of Tohoku University, Sendai, Japan. Because systemic deletion of EpoR is embryo-lethal,1 we rescued these mice with the EpoR that is exclusively expressed in erythroid progenitor cells under the regulatory domain of globin transcription factor 1 (GATA-1) (EpoR–/– rescued mice).22,23 The detailed procedures used to generate these mice were as follows. First, EpoR cDNA was ligated to a genomic fragment containing the hematopoietic regulatory domain of GATA-1 (GATA-1–HRD), which regulates the expression of EpoR in the hematopoietic progenitors. Second, these GATA-1–HRD-EpoR constructs were applied to produce transgenic mice, which were mated with EpoR+/– mice to establish the compound mutant EpoR+/– mice: GATA-1–HRD-EpoR. Finally, EpoR–/– rescued mice were generated by crossing these compound mutant mice and EpoR+/– mice. The EpoR was expressed under the control of an erythroid-specific promoter in the EpoR–/– rescued mice23; therefore, the expression was limited to the erythroid-lineage cells. By contrast, endogenous expression of EpoR mRNA was detected in most of the nonerythroid tissues in wild-type mice.22 Thus, EpoR–/– rescued mice are characterized by the absence of EpoR in the cardiovascular system but a normal hematopoietic system.
In the present study, a total of 120 male wild-type (C57BL/6) and 100 EpoR–/– rescued male mice (8 weeks old) were used. For the assessment of PH and histological evaluations, wild-type and EpoR–/– rescued mice were divided into 2 groups each (n=10 each for the 4 groups). One group was maintained in room air (21% O2), and the other group was exposed to hypoxia (10% O2) for 3 weeks. For Kaplan-Meier analysis, additional groups of mice were used (n=15 each for the 4 groups).
Bone Marrow Transplantation
Transgenic mice constitutively expressing green fluorescent protein (GFP) under the transcriptional regulation of an endothelial cell–specific promoter (Tie2-GFP mice) were obtained from Jackson Laboratory (Bar Harbor, Me). Bone marrow transplantation was performed as previously described.15 Briefly, recipient mice were lethally irradiated and received an intravenous injection of 5x106 donor bone marrow cells suspended in 100 µL calcium- and magnesium-free phosphate-buffered saline with 2% fetal bovine serum (FBS). Six weeks after the transplantation, these mice were transferred to hypoxic chambers (10% O2) and were maintained for 3 weeks as previously described.24
Measurements
Mice were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (8 mg/kg). Right ventricular systolic pressure (RVSP) was measured by insertion of a 25-gauge needle connected to a pressure transducer. Hematocrit was measured by use of an automatic hemocytometer (Nihon-Kohden, Tokyo, Japan). For morphometric analysis, tissue sections were prepared from the formalin-fixed and paraffin-embedded left lung, stained with elastica Masson, and assessed by microscopy. Pulmonary arteries adjacent to an airway distal to the respiratory bronchiole were evaluated as previously reported in a modified protocol.25 Briefly, the arteries were considered muscularized if they had a distinct double elastic lamina visible for at least half the diameter in the vessel cross section. The percentage of vessels with double elastic lamina was calculated as the number of muscularized vessels per total number of vessels counted. In each section, a total of 60 vessels were examined by use of a computer-assisted imaging system (DXM1200 with ACT-1 software, Nikon, Tokyo, Japan). This analysis was performed separately for different categories (external diameters, 25 to 60 µm and 60 to 100 µm). For immunohistological staining, monoclonal antibody to 
-smooth muscle actin (SMA, 1:300, DAKO, Denmark) was used as the primary antibody.
Immunofluorescence Staining
Immunofluorescence staining was performed on 4% paraformaldehyde–fixed frozen sections. The primary antibodies used were anti-EpoR (1:50, Santa Cruz Biotechnology, Inc, Santa Cruz, Calif), anti-mouse CD31 (1:400, BD PharMingen, San Diego, Calif), and anti-GFP (1:1000, Molecular Probes). Subsequently, Alexa Fluor 488– or Alexa Fluor 594–labeled secondary antibodies and Prolong antifade reagent with DAPI (Molecular Probes) were used. As a negative control, species- and isotype-matched immunoglobulin G was used in place of the primary antibody. Slides were viewed with a confocal fluorescence microscope (Fluoview FV1000, Olympus, Tokyo, Japan).
Flow Cytometry and EPC Culture Assay
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation with Nycoprep Animal 1.077 (Axis-Shield). To quantify the number of Flk-1+/CD133+ cells, we used phycoerythrin-labeled anti-mouse Flk-1, FITC-labeled anti-mouse CD133 (eBioscience, San Diego, Calif), and biotinylated anti-mouse lineage antibodies (Mac-1, Gr-1, B220, CD4, CD8, and Ter119, BD PharMingen).12 Quantitative analysis was performed by a fluorescence-activated cell sorter (FACScalibur, Becton Dickinson, San Jose, Calif). For EPC culture, isolated PBMCs (5x106 cells per well) were suspended in Medium-199 supplemented with 20% FBS, brain pituitary extract, antibiotics, 100 ng/mL VEGF, and 50 ng/mL basic fibroblast growth factor (R&D Systems, Minneapolis, Minn) and cultured on fibronectin-coated chamber slides (BioCoat, Becton Dickinson) for 7 days.12,26 To confirm the incorporation of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)-labeled acetylated LDL (DiI-AcLDL), cultured cells were incubated in medium containing 2 µg/mL DiI-AcLDL (Molecular Probes) for 3 hours at 37°C. Endothelium-like cells were identified by the uptake of DiI-AcLDL and Flk-1 expression.12 The expression of EpoR on endothelium-like cells was confirmed by double staining with biotinylated anti-mouse EpoR antibodies (1:50, R&D Systems) and anti-Flk-1 (VEGF receptor-2, 1:200, Santa Cruz Biochemicals).26 Endothelium-like cells (1x106 cells per mouse) were labeled with CellTracker CM-DiI (Molecular Probes, Eugene, Ore),26 suspended in 100 µL calcium- and magnesium-free phosphate-buffered saline with 2% FBS, and injected into the tail vein of hypoxic mice.
Western Blotting
Cell lysates from lung homogenates were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Millipore). Subsequently, the membranes were probed with antibodies to mouse EpoR (Santa Cruz Biochemicals), endothelial nitric oxide synthase (eNOS, BD Biosciences), and ß-actin (Cell Signaling, Danvers, Mass). Signals were visualized by the ECL detection system (Amersham Biosciences, Uppsala, Sweden).
Statistical Analysis
Quantitative results were expressed as mean±SD. Comparisons of parameters among the 2 or 3 groups were made by 1-way analysis of variance, and comparisons of the different oxygen conditions of parameters between the 2 genotypes were made by 2-way analysis of variance, followed by a post hoc analysis using the Bonferroni test. The Kaplan-Meier method was used to make survival curves, and the survival curves were compared by use of the log-rank test. A value of P<0.05 was considered to be statistically significant. Statistical analyses were performed by use of the StatView statistical package (StatView 5.0, SAS Institute Inc).
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the article as written.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
EpoR Deficiency Promotes PH and Pulmonary Vascular Remodeling
Under normoxic conditions, RVSP and right ventricular hypertrophy (RVH) were comparable between wild-type and EpoR–/– rescued mice (Figure 1A–1C). However, after the exposure to hypoxia (10% O2 for 3 weeks), RVSP was significantly higher and RVH was more accelerated in EpoR–/– rescued mice (Figure 1A through 1C), whereas the hematocrit was comparable between the 2 groups (Figure 1D). In addition, survival was significantly impaired in EpoR–/– rescued mice under chronic hypoxia (Figure 1E). In both groups, most animals that died showed ascites, RVH, and dilatation, suggesting that the main cause of death was right ventricular failure.
|
Histological examination showed that in wild-type mice, chronic hypoxia caused small-vessel muscularization, whereas in EpoR–/– rescued mice (although the extent of muscularization under normoxia was similar to that found in wild-type mice), the hypoxia-induced muscularization was significantly accelerated (Figures 2 and 3
). Immunostaining of lung sections showed that the hyperplastic cell population consisted of smooth muscle cells, inasmuch as they expressed SMA (Figure 2).
|
|
Impaired Mobilization of EPCs in EpoR–/– Rescued Mice
To compare the effect of hypoxia on the mobilization of EPCs between wild-type and EpoR–/– rescued mice, fluorescence-activated cell sorter analysis was performed in the peripheral blood. The number of EPCs, when defined as Flk-1+/CD133+ cells in PBMCs,27,28 was significantly increased under hypoxic conditions in wild-type mice but not in EpoR–/– rescued mice (Figure 4A). Similarly, hypoxia significantly increased the number of DiI-AcLDL+/Flk-1+ endothelium-like cells cultivated from PBMCs in wild-type mice but not in EpoR–/– rescued mice (Figure 4B). Importantly, cultivated endothelium-like cells from wild-type mice expressed EpoR; however, this was not the case for the cells from EpoR–/– rescued mice (Figure 4C). To further confirm the incorporation of bone marrow–derived endothelium-like cells into the pulmonary vessels, endothelium-like cells cultivated from mononuclear cells were intravenously injected into the wild-type mice that had already been exposed to hypoxia (10% O2) for 7 days. After additional exposure to hypoxia for 7 days, incorporation of the injected cells into the pulmonary endothelium was assessed by confocal microscopy (Figure 4D). Actual incorporation of infused cells from wild-type and EpoR–/– rescued mice into pulmonary endothelial cells was confirmed by immunostaining for CD31. Importantly, the number of the CD31-positive cells migrating to the pulmonary endothelium was significantly less in the cells from EpoR–/– rescued mice than in cells from wild-type mice (Figure 4E).
|
Bone Marrow–Derived EPCs Incorporated Into Pulmonary Endothelium Inhibit Development of PH
To confirm the incorporation of bone marrow–derived EPCs into pulmonary vessels in vivo, wild-type mice were lethally irradiated, transplanted with bone marrow cells from Tie2-GFP transgenic mice, and bred under hypoxic conditions. After 3 weeks of hypoxia, we found that GFP-positive endothelial cells were incorporated into the pulmonary endothelium (Figure 5A). The number of the GFP-positive endothelial cells that were incorporated into the pulmonary endothelium was significantly increased by hypoxic exposure compared with control conditions (Figure 5B).
|
To further examine whether the impaired mobilization and incorporation of bone marrow–derived EPCs in EpoR–/– rescued mice was involved in the development of severe PH, EpoR–/– rescued mice were lethally irradiated and then transplanted with bone marrow cells from wild-type or EpoR–/– rescued mice. As a control, wild-type mice reconstituted with wild-type bone marrow cells were prepared. After 6 weeks, these mice were exposed to hypoxia for 3 weeks. Hemodynamic analysis revealed that the development of PH, when assessed by RVSP and RVH, was partially ameliorated in EpoR–/– rescued mice transplanted with wild-type bone marrow cells (Figure 5C). Furthermore, the degree of pulmonary vessel muscularization (diameter, 25 µm to 60 µm) was also ameliorated in this group, whereas hematocrit values were comparable among the 3 groups (Figure 5D).
Impaired Response of Pulmonary Endothelial Cells in EpoR–/– Rescued Mice
To further elucidate any other mechanism that promotes PH in EpoR–/– rescued mice, we focused on the response of pulmonary endothelial cells to hypoxic exposure. The expression of EpoR was absent in pulmonary endothelial cells from EpoR–/– rescued mice, whereas the expression was enhanced by hypoxic exposure in wild-type mice (Figure 6). Moreover, because chronic hypoxia has been reported to increase eNOS protein in rat lungs,29 we evaluated the expression of eNOS. After 3 weeks of hypoxia, lung eNOS protein expression was increased in wild-type mice but not in EpoR–/– rescued mice (Figure 7).
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The novel finding of the present study is that the mobilization of EPCs from the bone marrow and their incorporation into the pulmonary endothelium are impaired in EpoR–/– rescued mice, with a resultant potentiation of PH and pulmonary vascular remodeling in response to chronic hypoxia. To the best of our knowledge, this is the first study demonstrating that the endogenous Epo/EpoR system exerts protective effects on pulmonary endothelium and its progenitors and inhibits the development of hypoxia-induced PH.
Epo Mobilizes EPCs and Repairs Pulmonary Endothelium
In the present study, ex vivo–cultivated peripheral blood–derived EPCs showed the expression of EpoR in wild-type mice but not in EpoR–/– rescued mice. The lack of an effect of Epo may involve the progression of pulmonary vascular remodeling that is due to impairment in the mobilization of EPCs and their recruitment to the injured pulmonary endothelium. This notion is supported by the present in vivo findings. Indeed, mobilization of EPCs, defined as Flk-1+/CD133+ cells in the peripheral blood and EPC culture assay, was impaired in EpoR–/– rescued mice. Intravenously infused bone marrow–derived EPCs were incorporated into the pulmonary endothelium; this process was significantly impaired in the EPCs from EpoR–/– rescued mice. Moreover, GFP-positive cells were incorporated into the pulmonary endothelium in chimeric mice that were reconstituted with bone marrow cells from Tie2-GFP transgenic mice. The expression of GFP is regulated by the Tie2 promoter and therefore identifies bone marrow–derived differentiated endothelial cells and EPCs.15 These findings are in line with findings in previous studies showing that circulating EPCs contribute to the endogenous vascular repair process and play an important role in inhibiting vascular remodeling.30 In addition, Davie et al31 demonstrated the incorporation of c-kit–positive progenitor cells into the pulmonary vessels under hypoxic conditions. Although the number of bone marrow–derived endothelial cells in the lung field was relatively small (
3% to 5%) compared with that in the hind-limb ischemia or tumor angiogenesis model,14,32 bone marrow–derived cells are likely to contribute to pulmonary endothelial repair not only by incorporating into the endothelial cells but also by improving the functions of the resident pulmonary endothelial cells through paracrine effects.33 EPCs also are reported to express eNOS and produce nitric oxide (NO).34 Indeed, the concept that bone marrow–derived endothelial cells could repair the pulmonary endothelium and ameliorate PH, especially through paracrine effects, has recently been proposed.20,21 By contrast, defective mobilization and recruitment of EPCs in EpoR–/– rescued mice may lead to the potentiation of PH in response to chronic hypoxia. Indeed, it has been recently reported that the number of circulating EPCs is associated with endothelial dysfunction in humans.35 Taken together, Epo may serve as a cytokine that elicits EPC mobilization, promoting the repair process of the injured pulmonary endothelium and thus inhibiting the development of PH.
Epo Has Direct Protective Effects on Pulmonary Endothelial Cells
Antiinflammatory and antiapoptotic effects on pulmonary endothelial cells have been shown to prevent the development of PH in rats.36,37 In line with these findings, we observed that lack of EpoR expression on pulmonary endothelium accelerates pulmonary vascular remodeling in EpoR–/– rescued mice; this occurrence may be partly due to the lack of direct effects of Epo on pulmonary endothelial cells.38–40 By contrast, the expression of EpoR was upregulated by hypoxia in wild-type mice. A similar observation has been previously reported with regard to human umbilical vein endothelial cells in vitro, where EpoR expression was induced by Epo and hypoxia.41 Moreover, parallel increases in eNOS expression and NO production in response to Epo were observed during hypoxia.41 An increase in the plasma level of Epo under hypoxic conditions combined with an upregulation of EpoR on pulmonary endothelial cells may augment the endothelial responses. In addition, the induction of eNOS and increased endothelial NO production by Epo may allow the pulmonary vasculature to recover blood flow and ameliorate PH.42 Importantly, these endothelial responses were absent in EpoR–/– rescued mice with accelerated PH and pulmonary vascular remodeling. Taken together, Epo has direct effects on pulmonary endothelial cells in addition to indirect effects on the recruitment of cells from bone marrow. All these effects of Epo may help to protect and maintain endothelial function and to inhibit pulmonary vascular remodeling under chronic hypoxia.
Limitations of the Present Study
Several limitations should be mentioned for the present study. First, the hypoxia-induced PH model may not fully represent primary PH in humans because this model shows a considerably high hematocrit and blood viscosity.16 Epo has been thought to increase these parameters, with a resultant development of PH.8 However, in the present study, RVSP and RVH were accelerated in EpoR–/– rescued mice in response to chronic hypoxia compared with wild-type mice, despite the comparable increase in hematocrit between the 2 strains. Furthermore, it has previously been shown that pulmonary arterial pressure and RVH are not increased in Epo-treated rats despite a significant increase in hematocrit and blood viscosity.43 Taken together, these results suggest that hypoxia-induced PH cannot be explained by simple polycythemia. Second, the mechanisms for the beneficial effects of Epo have been examined in only 1 model (hypoxia-induced PH) by comparing wild-type and EpoR–/– rescued mice. Thus, the importance of the endogenous Epo/EpoR system should be confirmed in other PH models with different etiologies (eg, bone morphogenetic protein receptor-2 [BMPR2]–heterozygous mutant [BMPR2+/–] mice44), although the same mechanisms for the protective effects of the Epo/EpoR system may be expected, especially when nonerythropoietic derivatives of Epo are used.45
Clinical Implications and Conclusions
In the present study, we were able to demonstrate that the endogenous Epo/EpoR system exerts important protective effects against the development of hypoxia-induced PH through mobilization of bone marrow–derived EPCs and stimulation of preexisting pulmonary endothelial cells. This is in line with our recent finding of the protective role of the endogenous Epo system in patients with acute myocardial infarction.7 Indeed, recent studies have shown that Epo increases the number of EPCs in humans46 and that Epo has an ischemia-induced angiogenic potential during retinal angiogenesis in diabetic patients.47 Therefore, the present findings suggest that the therapeutic use of Epo might be useful for the treatment of human diseases.48 However, further careful considerations should be made before Epo is applied in the clinical setting.
In conclusion, the present study demonstrates an important protective role of the endogenous Epo/EpoR system in the mobilization and incorporation of EPCs into the pulmonary endothelium and in the maintenance of pulmonary endothelial integrity in the pathogenesis of hypoxia-induced PH.
|
Acknowledgments |
|---|
This study was supported in part by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (16209027, 16659192), the Japanese Ministry of Health, Labor, and Welfare, Tokyo, Japan, and the Japan Foundation of Cardiovascular Research, Tokyo, Japan.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995; 83: 59–67.[CrossRef][Medline] [Order article via Infotrieve]
2. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994; 91: 3974–3978.
3. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004; 18: 1031–1033.
4. Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998; 253: 26–32.[CrossRef][Medline] [Order article via Infotrieve]
5. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003; 100: 4802–4806.
6. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000; 35: 1737–1744.
7. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, Kunii H, Yamao H, Komatsu N, Yui M, Tada H, Sakuma M, Watanabe J, Ichihara T, Shirato K. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45: 1406–1412.
8. Hasegawa J, Wagner KF, Karp D, Li D, Shibata J, Heringlake M, Bahlmann L, Depping R, Fandrey J, Schmucker P, Uhlig S. Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. Am J Respir Crit Care Med. 2004; 169: 829–835.
9. Petit RD, Warburton RR, Ou LC, Brinck-Johnson T, Hill NS. Exogenous erythropoietin fails to augment hypoxic pulmonary hypertension in rats. Respir Physiol. 1993; 91: 271–282.[CrossRef][Medline] [Order article via Infotrieve]
10. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993; 43: 1010–1014.[Medline] [Order article via Infotrieve]
11. Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996; 50: 481–488.[Medline] [Order article via Infotrieve]
12. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003; 102: 1340–1346.
13. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase–dependent manner. Cardiovasc Res. 2005; 68: 299–306.
14. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–967.
15. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85: 221–228.
16. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest. 2000; 106: 733–738.[Medline] [Order article via Infotrieve]
17. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest. 1998; 101: 2468–2477.[Medline] [Order article via Infotrieve]
18. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992; 12: 5447–5454.
19. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow–derived endothelial progenitor cells. EMBO J. 1999; 18: 3964–3972.[CrossRef][Medline] [Order article via Infotrieve]
20. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara T, Hara H, Mori H. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation. 2003; 108: 889–895.
21. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow–derived endothelium-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005; 96: 442–450.
22. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002; 100: 2279–2288.
23. Suzuki N, Suwabe N, Ohneda O, Obara N, Imagawa S, Pan X, Motohashi H, Yamamoto M. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood. 2003: 102; 3575–3583.
24. Katayose D, Ohe M, Yamauchi K, Ogata M, Shirato K, Fujita H, Shibahara S, Takishima T. Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol. 1993; 264: L100–L106.[Medline] [Order article via Infotrieve]
25. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT1B receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT1B–receptor knockout mice and the 5-HT1B/1D–receptor antagonist GR127935. Circ Res. 2001; 89: 1231–1239.
26. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003; 9: 1370–1376.[CrossRef][Medline] [Order article via Infotrieve]
27. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000; 95: 952–958.
28. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ Res. 2004; 95: 343–353.
29. Le Cras TD, Tyler RC, Horan MP, Morris KG, Tuder RM, McMurtry IF, Johns RA, Abman SH. Effects of chronic hypoxia and altered hemodynamics on endothelial nitric oxide synthase expression in the adult rat lung. J Clin Invest. 1998; 101: 795–801.[Medline] [Order article via Infotrieve]
30. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, Isner JM, Asahara T, Losordo DW. Estrogen-mediated, endothelial nitric oxide synthase–dependent mobilization of bone marrow–derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003; 108: 3115–3121.
31. Davie NJ, Crossno JT Jr, Frid MG, Hofmeister SE, Reeves JT, Hyde DM, Carpenter TC, Brunetti JA, McNiece IK, Stenmark KR. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol. 2004; 286: L668–L678.
32. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001; 7: 1194–1201.[CrossRef][Medline] [Order article via Infotrieve]
33. He T, Peterson TE, Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol. 2005; 289: H968–H972.
34. Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. Transplanted cord blood–derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest. 2000; 105: 1527–1536.[Medline] [Order article via Infotrieve]
35. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593–600.
36. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshita A. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004; 94: 385–393.
37. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, Yutani C, Yamagishi M, Kimura H, Kangawa K. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004; 170: 1204–1211.
38. Dudley AC, Thomas DM, Best J, Jenkins A. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J. 2005; 390: 427–436.[CrossRef][Medline] [Order article via Infotrieve]
39. Kano A, Wolfgang MJ, Gao Q, Jacoby J, Chai GX, Hansen W, Iwamoto Y, Pober JS, Flavell RA, Fu XY. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J Exp Med. 2003; 198: 1517–1525.
40. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999; 274: 22165–22169.
41. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004; 104: 2073–2080.
42. Champion HC, Bivalacqua TJ, D’Souza FM, Ortiz LA, Jeter JR, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo: effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999; 84: 1422–1432.
43. Petit RD, Warburton RR, Ou LC, Hill NS. Pulmonary vascular adaptations to augmented polycythemia during chronic hypoxia. J Appl Physiol. 1995; 79: 229–235.
44. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005; 112: 553–562.
45. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004; 305: 239–242.
46. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood. 2004; 103: 921–926.
47. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005; 353: 782–792.
48. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005; 293: 90–95.
 |
|
 |
|
  V. R. Gordeuk, A. Campbell, S. Rana, M. Nouraie, X. Niu, C. P. Minniti, C. Sable, D. Darbari, N. Dham, O. Onyekwere, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease Blood, November 19, 2009; 114(21): 4639 - 4644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Vaziri and X. J. Zhou Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease Nephrol. Dial. Transplant., April 1, 2009; 24(4): 1082 - 1088. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Unal, M. Sipahioglu, F. Oguz, M. Kaya, H. Kucuk, B. Tokgoz, H. Buyukoglan, O. Oymak, and C. Utas PULMONARY HYPERTENSION IN PERITONEAL DIALYSIS PATIENTS: PREVALENCE AND RISK FACTORS Perit. Dial. Int., March 1, 2009; 29(2): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Satoh, Y. Fukumoto, M. Nakano, K. Sugimura, J. Nawata, J. Demachi, A. Karibe, Y. Kagaya, N. Ishii, K. Sugamura, et al. Statin ameliorates hypoxia-induced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1 Cardiovasc Res, January 1, 2009; 81(1): 226 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Sears, G. Hoppe, Q. Ebrahem, and B. Anand-Apte Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy PNAS, December 16, 2008; 105(50): 19898 - 19903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bi, J. Guo, A. Marlier, S. R. Lin, and L. G. Cantley Erythropoietin expands a stromal cell population that can mediate renoprotection Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1017 - F1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Weiss, J. K. Kolls, L. A. Ortiz, A. Panoskaltsis-Mortari, and D. J. Prockop Stem Cells and Cell Therapies in Lung Biology and Lung Diseases Proceedings of the ATS, July 15, 2008; 5(5): 637 - 667. [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhang, J. Zhang, O. W. Moe, and C. C. W. Hsia Synergistic upregulation of erythropoietin receptor (EPO-R) expression by sense and antisense EPO-R transcripts in the canine lung PNAS, May 27, 2008; 105(21): 7612 - 7617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Shimokawa Bone Marrow-Derived Matrix Metalloproteinase-14: A Novel Target for Plaque Stability Circulation, February 19, 2008; 117(7): 863 - 865. [Full Text] [PDF]
|
|
|
|
|
|
K. Satoh and B. C. Berk Circulating smooth muscle progenitor cells: novel players in plaque stability Cardiovasc Res, February 1, 2008; 77(3): 445 - 447. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. van Albada, G. J. du Marchie Sarvaas, J. Koster, M. C. Houwertjes, R. M. F. Berger, and R. G. Schoemaker Effects of erythropoietin on advanced pulmonary vascular remodelling Eur. Respir. J., January 1, 2008; 31(1): 126 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization Eur. Heart J., August 2, 2007; 28(16): 2018 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Pak, A. Aldashev, D. Welsh, and A. Peacock The effects of hypoxia on the cells of the pulmonary vasculature Eur. Respir. J., August 1, 2007; 30(2): 364 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhang, D. J. Bellotto, P. Ravikumar, O. W. Moe, R. T. Hogg, D. C. Hogg, A. S. Estrera, R. L. Johnson Jr., and C. C. W. Hsia Postpneumonectomy lung expansion elicits hypoxia-inducible factor-1{alpha} signaling Am J Physiol Lung Cell Mol Physiol, August 1, 2007; 293(2): L497 - L504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Balasubramaniam, C. F. Mervis, A. M. Maxey, N. E. Markham, and S. H. Abman Hyperoxia reduces bone marrow, circulating, and lung endothelial progenitor cells in the developing lung: implications for the pathogenesis of bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1073 - L1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. d'Uscio, L. A. Smith, A. V. Santhanam, D. Richardson, K. A. Nath, and Z. S. Katusic Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin Hypertension, May 1, 2007; 49(5): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Asaumi, Y. Kagaya, M. Takeda, N. Yamaguchi, H. Tada, K. Ito, J. Ohta, T. Shiroto, K. Shirato, N. Minegishi, et al. Protective Role of Endogenous Erythropoietin System in Nonhematopoietic Cells Against Pressure Overload-Induced Left Ventricular Dysfunction in Mice Circulation, April 17, 2007; 115(15): 2022 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Madeddu and C. Emanueli Switching on Reparative Angiogenesis: Essential Role of the Vascular Erythropoietin Receptor Circ. Res., March 16, 2007; 100(5): 599 - 601. [Full Text] [PDF]
|
|
|
|
|
|
M. Nakano, K. Satoh, Y. Fukumoto, Y. Ito, Y. Kagaya, N. Ishii, K. Sugamura, and H. Shimokawa Important Role of Erythropoietin Receptor to Promote VEGF Expression and Angiogenesis in Peripheral Ischemia in Mice Circ. Res., March 16, 2007; 100(5): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Davidson and D. M. Yellon Dissecting out the mechanism of cardioprotection by endogenous erthyropoietin using genetic engineering Cardiovasc Res, August 1, 2006; 71(3): 408 - 410. [Full Text] [PDF]
|
|
|
|
|
|
H. Tada, Y. Kagaya, M. Takeda, J. Ohta, Y. Asaumi, K. Satoh, K. Ito, A. Karibe, K. Shirato, N. Minegishi, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion Cardiovasc Res, August 1, 2006; 71(3): 466 - 477. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||